Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Effect of luseogliflozin on hepatic fat content in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective, single-arm trial (LEAD trial).

Sumida Y, Murotani K, Saito M, Tamasawa A, Osonoi Y, Yoneda M, Osonoi T.

Hepatol Res. 2019 Jan;49(1):64-71. doi: 10.1111/hepr.13236. Epub 2018 Aug 31.

PMID:
30051943
2.

Protective effects of the SGLT2 inhibitor luseogliflozin on pancreatic β-cells in db/db mice: The earlier and longer, the better.

Kimura T, Obata A, Shimoda M, Okauchi S, Kanda-Kimura Y, Nogami Y, Moriuchi S, Hirukawa H, Kohara K, Nakanishi S, Mune T, Kaku K, Kaneto H.

Diabetes Obes Metab. 2018 Oct;20(10):2442-2457. doi: 10.1111/dom.13400. Epub 2018 Jul 5.

PMID:
29873444
3.

Changes in heart rate in patients with type 2 diabetes mellitus after treatment with luseogliflozin: Subanalysis of placebo-controlled, double-blind clinical trials.

Sano M, Chen S, Imazeki H, Ochiai H, Seino Y.

J Diabetes Investig. 2018 May;9(3):638-641. doi: 10.1111/jdi.12726. Epub 2018 May 3.

4.

Effect of the sodium-glucose cotransporter 2 inhibitor luseogliflozin on pancreatic beta cell mass in db/db mice of different ages.

Takahashi K, Nakamura A, Miyoshi H, Nomoto H, Kitao N, Omori K, Yamamoto K, Cho KY, Terauchi Y, Atsumi T.

Sci Rep. 2018 May 1;8(1):6864. doi: 10.1038/s41598-018-25126-z.

5.

Pharmacokinetics and Pharmacodynamics of Luseogliflozin, a Selective SGLT2 Inhibitor, in Japanese Patients With Type 2 Diabetes With Mild to Severe Renal Impairment.

Samukawa Y, Haneda M, Seino Y, Sasaki T, Fukatsu A, Kubo Y, Sato Y, Sakai S.

Clin Pharmacol Drug Dev. 2018 Nov;7(8):820-828. doi: 10.1002/cpdd.456. Epub 2018 Apr 25.

7.

Efficacy and safety of luseogliflozin added to insulin therapy in Japanese patients with type 2 diabetes: a multicenter, 52-week, clinical study with a 16-week, double-blind period and a 36-week, open-label period.

Seino Y, Sasaki T, Fukatsu A, Imazeki H, Ochiai H, Sakai S.

Curr Med Res Opin. 2018 Jun;34(6):981-994. doi: 10.1080/03007995.2018.1441816. Epub 2018 Mar 20.

PMID:
29448833
8.

Luseogliflozin, an SGLT2 Inhibitor, in Japanese Patients With Mild/Moderate Hepatic Impairment: A Pharmacokinetic Study.

Samukawa Y, Sata M, Furihata K, Ito T, Ueda N, Ochiai H, Sakai S, Kumagai Y.

Clin Pharmacol Drug Dev. 2017 Sep;6(5):439-447. doi: 10.1002/cpdd.364. Epub 2017 Aug 7.

PMID:
28783873
9.

The SGLT2 Inhibitor Luseogliflozin Rapidly Normalizes Aortic mRNA Levels of Inflammation-Related but Not Lipid-Metabolism-Related Genes and Suppresses Atherosclerosis in Diabetic ApoE KO Mice.

Nakatsu Y, Kokubo H, Bumdelger B, Yoshizumi M, Yamamotoya T, Matsunaga Y, Ueda K, Inoue Y, Inoue MK, Fujishiro M, Kushiyama A, Ono H, Sakoda H, Asano T.

Int J Mol Sci. 2017 Aug 4;18(8). pii: E1704. doi: 10.3390/ijms18081704.

10.
11.

Sodium glucose co-transporter 2 inhibitor luseogliflozin in the management of type 2 diabetes: a drug safety evaluation.

Yabe D, Hamamoto Y, Seino Y, Kuwata H, Kurose T, Seino Y.

Expert Opin Drug Saf. 2017 Oct;16(10):1211-1218. doi: 10.1080/14740338.2017.1359252. Epub 2017 Aug 18. Review. Erratum in: Expert Opin Drug Saf. 2017 Oct;16(10 ):1219.

PMID:
28741382
12.

Luseogliflozin improves liver fat deposition compared to metformin in type 2 diabetes patients with non-alcoholic fatty liver disease: A prospective randomized controlled pilot study.

Shibuya T, Fushimi N, Kawai M, Yoshida Y, Hachiya H, Ito S, Kawai H, Ohashi N, Mori A.

Diabetes Obes Metab. 2018 Feb;20(2):438-442. doi: 10.1111/dom.13061. Epub 2017 Aug 22.

PMID:
28719078
14.

Luseogliflozin reduces epicardial fat accumulation in patients with type 2 diabetes: a pilot study.

Bouchi R, Terashima M, Sasahara Y, Asakawa M, Fukuda T, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y.

Cardiovasc Diabetol. 2017 Mar 3;16(1):32. doi: 10.1186/s12933-017-0516-8.

15.

Effect of a selective SGLT2 inhibitor, luseogliflozin, on circadian rhythm of sympathetic nervous function and locomotor activities in metabolic syndrome rats.

Rahman A, Fujisawa Y, Nakano D, Hitomi H, Nishiyama A.

Clin Exp Pharmacol Physiol. 2017 Apr;44(4):522-525. doi: 10.1111/1440-1681.12725.

PMID:
28063156
16.

A simple and rapid LC-MS/MS method for quantitation of luseogliflozin in rat plasma and its application to a PK study.

Kobuchi S, Matsuno M, Kawamoto M, Kojima N, Ito Y, Yamashita M, Sakaeda T.

Bioanalysis. 2017 Jan;9(2):163-171.

PMID:
27960548
17.

SGLT2 inhibitor (Luseogliflozin): a new mechanism for treating type 2 diabetes mellitus and therapeutic potential to prevent the progression of diabetic complications.

Kojima N, Samukawa Y, Takahashi T.

Nihon Yakurigaku Zasshi. 2016;148(5):253-258. doi: 10.1254/fpj.148.253. Japanese. No abstract available.

PMID:
27803438
18.

Luseogliflozin, A Sodium Glucose Co-transporter 2 Inhibitor, Alleviates Hepatic Impairment in Japanese Patients with Type 2 Diabetes.

Kusunoki M, Natsume Y, Sato D, Tsutsui H, Miyata T, Tsutsumi K, Suga T, Oshida Y.

Drug Res (Stuttg). 2016 Nov;66(11):603-606. Epub 2016 Sep 14.

PMID:
27626603
19.

Metabolite profiling and enzyme reaction phenotyping of luseogliflozin, a sodium-glucose cotransporter 2 inhibitor, in humans.

Miyata A, Hasegawa M, Hachiuma K, Mori H, Horiuchi N, Mizuno-Yasuhira A, Chino Y, Jingu S, Sakai S, Samukawa Y, Nakai Y, Yamaguchi JI.

Xenobiotica. 2017 Apr;47(4):332-345. doi: 10.1080/00498254.2016.1193263. Epub 2016 Jun 27.

PMID:
27347703
20.

In vitro evaluation of potential drug interactions mediated by cytochrome P450 and transporters for luseogliflozin, an SGLT2 inhibitor.

Chino Y, Hasegawa M, Fukasawa Y, Mano Y, Bando K, Miyata A, Nakai Y, Endo H, Yamaguchi JI.

Xenobiotica. 2017 Apr;47(4):314-323. doi: 10.1080/00498254.2016.1193913. Epub 2016 Jun 20.

PMID:
27324291

Supplemental Content

Loading ...
Support Center